Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world

Table 2 Summary of overall survival

	All patients (n = 55)	Group A (n = 20)	Group B (n = 21)	Group C (n = 14)
Patients with event	16 (29.1%)	8 (40.0%)	4 (19.0%)	4 (28.6%)
Patients without event	39 (70.9%)	12 (60.0%)	17 (81.0%)	10 (71.4%)
Time to event (mo)
Median	-	-	-	-
95%CI	27.0, -	9.0, -	27.0, -	12.0, -
25% and 75%-ile	15.50, -	10.50, -	27.00, -	12.50, -
Min-max	0.5-39	5-26	2.6-39	0.5-35
12 mo probability (95%CI)	78.8 (65.1-87.7)	65.0 (40.3-81.5)	95.0 (69.5-99.3)	75.0 (40.8-91.2)
18 mo probability (95%CI)	72.7 (58.3-82.9)	60.0 (35.7-77.6)	89.7 (64.8-97.3)	66.7 (33.7-86.0)

Group A: Chemoradiotherapy plus pembrolizumab. Group B: Neoadjuvant therapy plus pembrolizumab. Group C: Chemotherapy plus pembrolizumab. CI: Confidence interval.